Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IO Biotech, Inc.IOBT · Entity 8764 | Director | June 05, 2025 | June 06, 2025 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IO Biotech, Inc.
Report date June 05, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-06-05 | Direct | 35,144 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 35,144 · Balance 35,144 F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.
SUTRO BIOPHARMA, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2036-06-05 | Direct | 10,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 20:16 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001891841-26-000002 · form4-06092026_080631.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 21:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001891841-25-000005 · form4-12292025_091243.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-12-23 F1 · derivative.exercise_date: The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001415889-25-016464 · form4-06102025_080632.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:27 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 35,144 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000905148-25-002033 · form4.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,144 Underlying: Common Stock · 35,144 shares Expires 2035-06-05 F1 · derivative.exercise_date: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 11:53 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 15,000 | $1.39 | $20,884.50 |
DisclosureSEC source: 0000905148-25-001960 · form4.xml · nonDerivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · price: The transaction was executed in multiple trades in prices ranging from $1.37 to $1.40, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:18 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 45,642 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0000905148-24-001686 · form4.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,642 Underlying: Common Stock · 45,642 shares Expires 2034-06-06 F1 · derivative.exercise_date: These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001415889-24-016211 · form4-06102024_080615.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 22:02 UTC | IO Biotech, Inc. IOBT · Entity 8764 | GrantStock Option (Right to Buy) · Derivative | 64,238 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001140361-23-039937 · form4.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,238 Underlying: Common Stock · 64,238 shares Expires 2033-08-11 F1 · derivative.exercise_date: 1/36th of these options vest each month over three years, subject to the reporting person's continued service through each applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:51 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036479 · doc4.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 8, 2023, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2024 annual stockholders meeting or June 8, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:04 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-22-035207 · doc4.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 9,884 | $0.00 Strike: $17.56 | $0.00 |
DisclosureSEC source: 0001209191-21-066150 · doc4.xml · derivative · entry 2 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,884 Underlying: Common Stock · 9,884 shares Expires 2031-11-18 F2 · derivative.exercise_date: The option vests as to 15.59% of the total shares monthly beginning on December 19, 2021 through May 19, 2022, and 6.45% on June 2, 2022, with 100% of the total shares vested and exercisable on the issuer's 2022 annual meeting of stockholders, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 24,000 | $0.00 Strike: $17.56 | $0.00 |
DisclosureSEC source: 0001209191-21-066150 · doc4.xml · derivative · entry 1 Hunter Heidi · CIK 0001891841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, beginning on December 19, 2021, with 100% of the total shares vested and exercisable on November 19, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.